Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03169530 · ClinicalTrials.gov registry record · NA

Moderate Alcohol and Cardiovascular Health Trial

A NA study, sponsored by Beth Israel Deaconess Medical Center.

Terminated
Registry status
NA
Development phase
103
Enrollment target

NCT03169530: Clinical Trial NA study, sponsored by Beth Israel Deaconess Medical Center.

NCT03169530 is a NA study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 103 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03169530, a NA study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.

TERMINATED
Registry status
NA
Development phase
103 participants
Enrollment target

Study Summary

The Moderate Alcohol and Cardiovascular Health Trial (MACH15) is a multicenter, worldwide, randomized clinical trial of \~15 gm of alcohol daily versus abstention, using a balanced parallel design and single-blind assessment of all outcomes among approximately 7,800 participants aged 50 years and older with advanced cardiovascular risk. Intervention will average 6 years in duration with a common close-out date. Following recruitment and pre-screening, participants will attend a screening visit followed by a two-week abstention washout period, a baseline visit and randomization, and subsequent visits at 3 months, 6 months, 12 months, and then annually until close-out.

Primary Outcome

Time from baseline to a composite endpoint comprised of the first occurrence of a non-fatal myocardial infarction, non-fatal ischemic stroke, hospitalization for angina, coronary/carotid revascularization, or all-cause mortality.

Interventions

  • OTHER Alcohol

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2018-02-05
Est. Completion 2018-06-15
Phase NA

Why NCT03169530 stopped before completion

NCT03169530 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 1 intervention - of which Alcohol is the first listed.

NCT03169530 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03169530 about?

NCT03169530 is a clinical study titled "Moderate Alcohol and Cardiovascular Health Trial". The Moderate Alcohol and Cardiovascular Health Trial (MACH15) is a multicenter, worldwide, randomized clinical trial of \~15 gm of alcohol daily versus abstention, using a balanced parallel design and single-blind assessment of all outcomes among approximately 7,800 participants aged 50 years and ol...

What is the current status of trial NCT03169530?

This trial is currently terminated. It is a NA study. The enrollment target is 103 participants. The study started on 2018-02-05. Estimated completion is 2018-06-15.

What interventions are being tested in trial NCT03169530?

The interventions under investigation include: Alcohol (OTHER).

Who is sponsoring clinical trial NCT03169530?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03169530's enrollment target sits among peer trials

103 837th of 2000 higher than 1,164 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04690348 · 103 participants · Phase 2

    Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study

  • NCT05282277 · 103 participants · Phase 4

    Examining the Effects of Estradiol on Neural and Molecular Response to Reward

  • NCT05566769 · 103 participants · NA

    Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD

  • NCT05834478 · 103 participants · Phase 3

    Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03169530, the US trial registry maintained by the National Library of Medicine. NCT03169530 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.